NDC 00093-5955-06 — Arformoterol tartrate 15 ug/2mL Solution

🆔 Identity & classification

FDA NDC (as labeled) 0093-5955-06

Product NDC 0093-5955

11-digit billing NDC 00093595506

NCPDP billing unit ML — per mL (volume)

Application # ANDA200293

Established class (EPC) Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist

DEA schedule Non-controlled

Marketing category ANDA

Marketing status Discontinued

FDA listing status Discontinued by firm (certified through Oct 2025)

Route RESPIRATORY (INHALATION)

Dosage form SOLUTION

Substance ARFORMOTEROL TARTRATE

GCN Seq No 061579

GCN 97366

HICL code 034087

Ingredient (HICL) Arformoterol Tartrate

HIC1 code B

Therapeutic class — broad (HIC1) Respiratory System

HIC2 code B6

Therapeutic class — intermediate (HIC2) Drugs Affecting The Trachea And Bronchi (Cont3)

HIC3 code B6Y

Therapeutic class — specific (HIC3) Beta-Adrenergic Agents, Orally Inhaled,Long Acting

AHFS code 12:12.08.12

AHFS class Selective Beta-2-Adrenergic Agonists

FDB label name ARFORMOTEROL 15 MCG/2 ML SOLN

FDB brand name Arformoterol Tartrate

Legend status F — Federal legend — prescription drug or device

Why two NDCs? The FDA registers this code as 0093-5955-06 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-5955-06. Same drug, same package — only the format differs.

Where does this data come from?

Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.

Application holderTEVA PHARMACEUTICALS USA

FDA applicationANDA200293 (ANDA)

Labeler code00093

Product typeHuman Prescription Drug

Portfolio504 products on file

🔎 All NDCs from Teva Pharmaceuticals USA, Inc.

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).

Where does this data come from?

Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name ARFORMOTEROL 15 MCG/2 ML SOLN Ingredient Arformoterol Tartrate

📖 What it is MedlinePlus · NLM

Arformoterol inhalation is used to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease (COPD; a group of lung diseases, which includes chronic bronchitis and emphysema). Arformoterol is in a class of medications called long-acting beta agonists (LABAs). It works by relaxing and opening air passages in the lungs, making it easier to breathe.

Read the full MedlinePlus article ↗

📗 Our plain-language guide HelloPharmacist

No — arformoterol is a maintenance medication, not a rescue inhaler. It works slowly to keep your airways open over 12 hours, so it won't help fast enough during an acute attack. Y...
Can I use arformoterol if I'm having a sudden breathing attack?
Each dose comes in a small single-use liquid vial. You open the vial, pour the contents into your nebulizer cup, attach the tubing to your air compressor, and breathe in the mist t...
How exactly do I use the nebulizer for this medication?

📖 Read our full Arformoterol Oral Inhalation guide →

Patient education

📘 MedlinePlus patient leaflet ↗

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →

Where does this data come from?

Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.

Where does this data come from?

Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?

No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.

Why might an inactive ingredient be missing?

Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.

Can inactive ingredients matter?

Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price system	Per mL	Per package
Retail pharmacies payNADAC · weekly	$0.643	$77.15 / 120 ml
Medicaid paysCMS SDUD · 12 mo	No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly	No Part D plan price is available for this NDC in our data.
Medicare Part B allowsASP · J7605	$0.742 / J7605 unit	—

NADAC price history (per mL) — tap or hover for the price & month

▼ Down 79% over the last 22 months.

Where does this data come from?

NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🧾 Billing & reimbursement

FDA NDC (as labeled)0093-5955-06

11-digit billing NDC00093-5955-06

Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)

HCPCS J-codeJ7605

DescriptorARFORMOTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, 15 MICROGRAMS

Billing units / pkg0.5 units

Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)

Where does this data come from?

The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

🔁 Therapeutic equivalents

Product	Labeler	Pack	NADAC/unit	TE	Status	Price vs. this
Arformoterol Tartrate 15 ug/2mL 42571-0464-73	Micro	30 pouches	$0.615	AN	Availability likely	save 4%
arformoterol tartrate 15 ug/2mL 43598-0777-30	Dr.	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol Tartrate 15 ug/2mL 50742-0395-30	Ingenus	6 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol Tartrate 15 ug/2mL 60687-0770-83	American	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol tartrate 15 ug/2mL 62332-0633-30	Alembic	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol Tartrate 15 ug/2mL 62756-0277-02	Sun	6 pouches	$0.615	AN	Availability likely	save 4%
arformoterol tartrate 15 ug/2mL 69097-0168-53	Cipla	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol Tartrate Inhalation 15 ug/2mL 70436-0151-57	Slate	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol tartrate 15 ug/2mL 70748-0175-30	Lupin	30 pouches	$0.615	AN	Availability likely	save 4%
Arformoterol tartrate 15 ug/2mL 72266-0259-30	Fosun	30 pouches	$0.615	AN	Availability likely	save 4%
arformoterol tartrate 15 ug/2mL 72603-0208-30	NorthStar	30 pouches	$0.615	AN	Availability likely	save 4%
arformoterol tartrate 15 ug/2mL 70756-0612-60	Lifestar	60 pouches	$0.643	AN	Availability likely	—
Arformoterol Tartrate Inhalation 15 ug/2mL 73043-0052-60	Devatis,	60 pouches	$0.643	AN	Availability likely	—
Arformoterol tartrate 15 ug/2mLthis 00093-5955-06	Teva	12 pouches	$0.643	—	Discontinued	—
Arformoterol Tartrate Inhalation Solution 15 ug/2mL 73289-0072-03	Aucta	30 pouches	—	AN	FDA listed	—
Arformoterol Tartrate Inhalation Solution 15 ug/2mL 76204-0026-01	Ritedose	30 pouches	—	AN	FDA listed	—

About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.

Where does this data come from?

Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

📍

2026

Currently FDA-listed

listed with the FDA

🔓

·

Generic on the market

this product is a generic

✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?

Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Arformoterol Tartrate — the program that covers self-administered drugs. 9 manufacturers.

⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Arformoterol Tartrate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.

Period

Total Part D spend

$2.06M

Claims incl. refills

6.9K

Beneficiaries

3.1K

Spend / beneficiary

$656.45

Spend / claim

$300.25

Trend by period

💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Arformoterol Tartrate — the ingredient across all brands.

Top reported reactions

Dyspnoea52

Fatigue28

Pneumonia24

Cough20

Chronic Obstructive Pulmonary Disease19

Diarrhoea16

Asthenia15

Age at onset

Adult16

Elderly52

Reporter sex

Reports over time (by year) — tap or hover for the count & year

Most recent year is provisional (FAERS lags ~3 months).

Where does this data come from?

Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDC	Description	Per unit	Per pack	Marketing start	Status
00093-5955-06 You're viewing this	12 POUCH in 1 CARTON (0093-5955-06) / 5 AMPULE in 1 POUCH (0093-5955-45) / 2 mL in 1 AMPULE (0093-5955-19)	$0.6429 / mL	$77.14	2021-12-06	Discontinued by firm
00093-5955-56	30 POUCH in 1 CARTON (0093-5955-56) / 1 AMPULE in 1 POUCH (0093-5955-11) / 2 mL in 1 AMPULE	$0.6145 / mL	$36.87	2021-12-06	Discontinued by firm

Per mL, this pack runs about 5% above the cheapest pack (NDC 00093-5955-56, $0.6145 vs $0.6429 NADAC).

Pack size FAQ

What quantity is in NDC 00093-5955-06?

NDC 00093-5955-06 is listed by the FDA — 12 pouch in 1 carton / 5 ampule in 1 pouch / 2 ml in 1 ampule.

What NDC number is used to bill for this package of Arformoterol tartrate 15 ug/2mL Solution?

Bill NDC 00093-5955-06 — the 11-digit billing format is 00093595506. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

🧭 About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)

What data is (and isn’t) available for this NDC — tap to expand

NDC identity (package / product / labeler codes)	✓ Available
Labeler	✓ Available
Product & package description	✓ Available
Marketing category & status	✓ Available
Active ingredient / dosage form / route	✓ Available
FDA label (SPL via DailyMed)	— Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA.
Package photos	— Not published for this NDC The FDA label for this product carries no photos.
Inactive ingredients (structured)	— Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS)	✓ Available
Orange Book / therapeutic-equivalence data	— Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk	✓ Available
Medicaid utilization (CMS SDUD)	— Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.

“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no full label on this page?

No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.

What does the discontinued status mean for this NDC?

The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.

Is the NDC printed on the package the same as the 11-digit billing NDC?

Yes, they identify this exact package in different formats. The FDA registers it as 0093-5955-06, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 00093-5955-06, written without dashes as 00093595506. The Identity section at the top of this page lists every form of this code.

What do the three segments of this NDC mean?

In 00093-5955-06, the first segment (00093) is the labeler code FDA assigned to Teva Pharmaceuticals USA, Inc.; the middle segment (5955) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (06) identifies this exact package size and type. Together they name one specific package of one specific product.

Does this product come in other package sizes?

Yes — the FDA directory lists 1 other package presentation of this same product, including 30 pouches (00093-5955-56). Each has its own NDC and its own page — see the package list near the top of this page.

Who lists this product with the FDA?

Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.

Do I need a prescription for this product?

This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.

Does this product have a billing J-code?

Yes — this NDC cross-references HCPCS code J7605 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.

This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.

Where does this data come from?

Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.

📄 FDA label

📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.

🔗 Related NDC lookups

🧪 All Arformoterol Tartrate NDCsSame ingredient 🏭 All Teva labeler NDCsLabeler code 00093 📚 All Adrenergic beta2-Agonists [MoA], beta2-Adrenergic Agonist NDCsDrug class 🧾 J7605 billing & NDC crosswalkJ-code

💊 Related drugs in this class

Other drugs that share this product’s specific therapeutic class — Beta-Adrenergic Agents, Orally Inhaled,Long Acting.

Formoterol Fumarate 00093-4061-06 Salmeterol Xinafoate 00173-0521-00

Where does this data come from?

Other drugs sharing this product’s First Databank therapeutic class (HIC3). Each links to that NDC’s page in our directory.